Answers are grounded in this paper and cite their sources.
In the THOR trial (NCT03390504) Cohort 1, erdafitinib demonstrated significantly prolonged overall survival (OS) (median 12.1 versus 7.8 months) and reduced risk of death by 36% (hazard ratio 0.64, P = 0.005) compared with chemotherapy in metastatic urothelial carcinoma (mUC) patients with FGFR alterations who progressed after ≥ 1 prior treatments, including anti-PD-(L)1. There have been no reports of the Japanese subgroup results yet.
No takes yet. Share an insight, caveat, or question.
Matsubara et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: